ReviewPharmaceutics2021
Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Breaking Biological Barriers: Engineering Nanocarriers for Efficient Drug and Gene Delivery through Nano-Bio Interfaces and Biophysical Design.Applied physics reviews · 2026Article
- Iridium Nanoparticle-Gated Janus Nanomachines for Enzyme-Controlled Drug Delivery.ACS applied nano materials · 2026Article
- Polymeric Nanocarriers and Polymer-Assisted Delivery Platforms for Oleanolic Acid: Design Strategies, Controlled Release, Translational Challenges, and Clinical Perspectives.Micromachines · 2026Review
- Engineering β-cyclodextrin gels with nanoparticles: tunable assembly and multifunctional applications.Nanoscale advances · 2026Article
- Cyclodextrins: Synthesis, Pharmaceutical Applications, Drug Delivery Systems and Safety Perspectives.AAPS PharmSciTech · 2026Review
- Nanoparticle Clearance and New Horizons in Engineered Drug Delivery.Pharmaceutics · 2026Review
- Innovative Inclusion Complexes Clotrimazole: Hydroxypropyl-β-Cyclodextrin-Modified Polyurethane Networks as Carriers for Slow Drug Delivery.Biomedicines · 2026Article
- Enhancing Escin's Therapeutic Efficacy: A Nanoformulation Approach for Improved Stability and Anticancer Potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Using a Natural Clay Mineral as an Active Drug Carrier to Promote Hair Growth.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Revolutionizing healthcare with nanosensor technology.RSC advances · 2025Review
- A Review of Formulation Strategies for Cyclodextrin-Enhanced Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs).International journal of molecular sciences · 2025Review
- Targeting Ocular Biofilms with Plant-Derived Antimicrobials in the Era of Antibiotic Resistance.Molecules (Basel, Switzerland) · 2025Review
- Cyclodextrins as multifunctional tools for advanced biomaterials in tissue repair and regeneration.Bioactive materials · 2025Review
- Emerging Trends in Green Extraction Techniques, Chemical Modifications, and Drug Delivery Systems for Resveratrol.Antioxidants (Basel, Switzerland) · 2025Review
- Applications of Cyclodextrin-Based Drug Delivery Systems in Inflammation-Related Diseases.Pharmaceutics · 2025Review
- Cyclodextrins: Enhancing Drug Delivery, Solubility and Bioavailability for Modern Therapeutics.Pharmaceutics · 2025Review
- Nanosponges-road Less Explored Changing Drug Delivery Approach: An Explicative Review.Current pharmaceutical biotechnology · 2025Review
- Nanofibers in Glioma Therapy: Advances, Applications, and Overcoming Challenges.International journal of nanomedicine · 2025Review
- Cyclodextrin-based therapeutics delivery systems: A review of current clinical trials.Current research in pharmacology and drug discovery · 2025Review
- Recent Advances in Di-, Tri-Substituted Mono-Thiazoles, and Bis-Thiazoles: Factors Affecting Biological Activities, Future Aspects, and Challenges.Current topics in medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In drug delivery, one widely used way of overcoming the biopharmaceutical problems present in several active pharmaceutical ingredients, such as poor aqueous solubility, early instability, and low bioavailability, is the formation of inclusion compounds with cyclodextrins (CD). In recent years, the use of CD derivatives in combination with nanomaterials has shown to be a promising strategy for formulating new, optimized systems. The goals of this review are to give in-depth knowledge and critical appraisal of the main CD-modified or CD-based nanomaterials for drug delivery, such as lipid-based nanocarriers, natural and synthetic polymeric nanocarriers, nanosponges, graphene derivatives, mesoporous silica nanoparticles, plasmonic and magnetic nanoparticles, quantum dots and other miscellaneous systems such as nanovalves, metal-organic frameworks, Janus nanoparticles, and nanofibers. Special attention is given to nanosystems that achieve controlled drug release and increase their bioavailability during in vivo studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.